Abstract: The present invention addresses the problem of providing an angiogenesis promoter capable of exerting an excellent angiogenesis promoting effect without containing any growth factor. The present invention also addresses the problem of providing a therapeutic method. An angiogenesis promoter that comprises as an active ingredient at least one member selected from the group consisting of a gelatin derivative represented by formula 1 and a crosslinked product of the gelatin derivative: In formula 1: Gltn represents a gelatin residue; L represents a single bond or a divalent linking group; and R1 and R2 independently represent a hydrocarbon group having 1-20 carbon atoms or a hydrogen atom, provided that at least one of R1 and R2 represents the aforesaid hydrocarbon group.

Abstract: The adhesive includes a first agent that includes a gelatin derivative in which a hydrophobic group is bound to gelatin through an imino group represented by a formula 1: GltnNH-R1 and includes cyclodextrin; and a second agent that includes a crosslinking agent for the gelatin derivative. The cured product is resistant to swell in a physiological saline solution. In the formula 1, Gltn represents a residue of the gelatin, R1 represents the hydrophobic group, and NH represents the imino group binding to the residue and the hydrophobic group.

Abstract: A wound dressing material includes a particle having a crosslinked gelatin derivative, the gelatin derivative having the structure represented by the following formula (1): GltnNH—CHR1R2??(1) wherein “Gltn” represents a gelatin residue, R1 represents an alkyl group having 1-17 carbon atoms, and R2 represents a hydrogen atom or an alkyl group having 1-17 carbon atoms, and the particle having a particle size ranging from 1 to 1,000 ?m.

Abstract: An adhesive sheet includes cyclodextrin and a derivative polymer in which an alkyl group having a carbon number of 6 to 18 is introduced into a hydrophilic polymer, and at least a part of the alkyl group is in the form of inclusion with the cyclodextrin.

Abstract: The present invention provides a biological tissue adhesive sheet having excellent tissue adhesiveness. The biological tissue adhesive sheet according to an embodiment of the present invention includes a nonwoven fabric made of fibers containing a crosslinked cold-water fish gelatin. Thereby, the biological tissue adhesive sheet according to the present invention is superior in tissue adhesiveness and film strength to conventional medical sheets.

Abstract: The present invention provides a biological tissue adhesive sheet having excellent tissue adhesiveness. The biological tissue adhesive sheet according to an embodiment of the present invention includes a nonwoven fabric made of fibers containing a crosslinked gelatin derivative, and the gelatin derivative is represented by Formula 1: Gltn-NH-L-CHR1R2, wherein Gltn represents a gelatin residue, L represents a single bond or a divalent linking group, R1 and R2 are each independently a hydrocarbon group having 1 to 20 carbon atoms or a hydrogen atom, and at least one selected from the group consisting of R1 and R2 is the hydrocarbon group.

Abstract: The present invention addresses the problem of providing a powder that has excellent adhesive strength to biological tissue when applied to a wound-covering material or the like. The present invention also addresses the problem of providing a wound-covering material and an adhesion prevention material. The powder contains particles containing a crosslinked gelatin derivative, wherein the gelatin derivative has a structure represented by formula (1): GltnNH-L-CHR1R2 (in the formula, Gltn represents a residue of gelatin, L represents a single bond or a divalent linking group, R1 represents a hydrocarbon group having 1-20 carbon atoms, and R2 represents a hydrogen atom or a hydrocarbon group having 1-20 carbon atoms), the particles have an average sphericity of 1.45 or less, and the standard deviation of the sphericity of the particles is 0.25 or less.

Abstract: The present invention addresses the problem of providing an angiogenesis promoter capable of exerting an excellent angiogenesis promoting effect without containing any growth factor. The present invention also addresses the problem of providing a therapeutic method. An angiogenesis promoter that comprises as an active ingredient at least one member selected from the group consisting of a gelatin derivative represented by formula 1 and a crosslinked product of the gelatin derivative: In formula 1: Gltn represents a gelatin residue; L represents a single bond or a divalent linking group; and R1 and R2 independently represent a hydrocarbon group having 1-20 carbon atoms or a hydrogen atom, provided that at least one of R1 and R2 represents the aforesaid hydrocarbon group.

Abstract: An adhesion prevention material consisting of: (1) a first agent comprising a gelatin derivative, the gelatin derivative (a) including a structure represented by the following formula, GltnNH—CHR1R2, in the formula, Gltn represents a gelatin residue, R1 represents an alkyl group with 5 to 17 carbon atoms, and R2 represents a hydrogen atom or an alkyl group with 5 to 17 carbon atoms; (b) having imino group/amino group (molar ratio) of 1/99 to 30/70; and (c) having a weight average molecular weight of 10,000 to 50,000; and (2) a second agent comprising a crosslinker for the gelatin derivative.

Abstract: A method of hemostasis includes the step of applying a hemostatic agent to an affected site of a subject, the hemostatic agent consisting of a first agent comprising a gelatin derivative having a hydrophobic group bonded to the gelatin via an imino group, wherein the gelatin derivative has (a) a weight average molecular weight of from 10,000 to 50,000, (b) the hydrophobic group, which is an alkyl group having 6 to 18 carbon atoms; and (c) a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and a second agent including a crosslinking agent for the gelatin derivative.

Abstract: A wound dressing material includes a particle having a crosslinked gelatin derivative, the gelatin derivative having the structure represented by the following formula (1): GltnNH—CHR1R2??(1) wherein “Gltn” represents a gelatin residue, R1 represents an alkyl group having 1-17 carbon atoms, and R2 represents a hydrogen atom or an alkyl group having 1-17 carbon atoms, and the particle having a particle size ranging from 1 to 1,000 ?m.

Abstract: A surgical sealant consisting of (1) a first agent comprising a gelatin derivative, wherein the gelatin derivative (a) has a weight average molecular weight of from 10,000 to 50,000; (b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms; (c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and (d) comprises a structure represented by the following formula: GltnNH—CHR1R2, wherein “Gltn” represents a gelatin residue, R1 is the hydrophobic group, and R2 is a hydrogen atom or the hydrophobic group; and (2) a second agent comprising a crosslinking agent for the gelatin derivative.

Abstract: A surgical sealant consisting of (1) a first agent comprising a gelatin derivative, wherein the gelatin derivative (a) has a weight average molecular weight of from 10,000 to 50,000; (b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms; (c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and (d) comprises a structure represented by the following formula: GltnNH—CHR1R2, wherein “Gltn” represents a gelatin residue, R1 is the hydrophobic group, and R2 is a hydrogen atom or the hydrophobic group; and (2) a second agent comprising a crosslinking agent for the gelatin derivative.

Abstract: A surgical sealant comprising a first agent containing a hydrophobically-modified gelatin derived from a cold-water fish, and a second agent containing a water-soluble molecule for crosslinking, wherein the water-soluble molecule for crosslinking is at least one kind selected from the group consisting of poly acids and acid anhydrides having two or more active ester groups, and aldehyde compounds having two or more aldehyde groups, the hydrophobically-modified gelatin derived from a cold-water fish is a gelatin in which at least a part of amino groups of side chains of a gelatin derived from a cold-water fish has been substituted by hydrophobic groups, and the hydrophobic groups are linear chain aliphatic groups each having 8 to 18 carbon atoms, with a substitution rate (number of moles of hydrophobic groups/(total number of moles of hydrophobic groups and reactive amino groups in gelatin)×100) of 3 to 20 mol %.

Abstract: A method of hemostasis includes the step of applying a hemostatic agent to an affected site of a subject, the hemostatic agent consisting of a first agent comprising a gelatin derivative having a hydrophobic group bonded to the gelatin via an imino group, wherein the gelatin derivative has (a) a weight average molecular weight of from 10,000 to 50,000, (b) the hydrophobic group, which is an alkyl group having 6 to 18 carbon atoms; and (c) a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and a second agent including a crosslinking agent for the gelatin derivative.

Abstract: A surgical sealant comprising a first agent containing a hydrophobically-modified gelatin derived from a cold-water fish, and a second agent containing a water-soluble molecule for crosslinking, wherein the water-soluble molecule for crosslinking is at least one kind selected from the group consisting of poly acids and acid anhydrides having two or more active ester groups, and aldehyde compounds having two or more aldehyde groups, the hydrophobically-modified gelatin derived from a cold-water fish is a gelatin in which at least a part of amino groups of side chains of a gelatin derived from a cold-water fish has been substituted by hydrophobic groups, and the hydrophobic groups are linear chain aliphatic groups each having 8 to 18 carbon atoms, with a substitution rate (number of moles of hydrophobic groups/(total number of moles of hydrophobic groups and reactive amino groups in gelatin)×100) of 3 to 20 mol %.

Abstract: There is provided a tissue adhesive to be applied to a tissue by mixing an adhesive component including an aqueous solution of a fish-derived gelatin with a curative component including an aqueous solution of a water-soluble crosslinking reagent, wherein the water-soluble crosslinking reagent has an amide linkage or an ethylene glycol unit or a sugar chain in the molecular main chain thereof and has two or more of an active ester group or an acid anhydride or an aldehyde group.

Abstract: The present invention addresses the problem of providing: a two-component tissue adhesive having high adhesive strength and high biocompatibility; and a method for producing the two-component tissue adhesive. The present invention involves a two-component tissue adhesive comprising hydrophobically-modified gelatin as a first agent and a cross-linking reagent as a second agent. The hydrophobically-modified gelatin is provided with an amino group and a hydrophobic group on the side chain thereof, and the cross-linking reagent has two or more active ester groups or anhydrides within a single molecule.

Abstract: Provided is a bio-hybrid material that does not cause elution of nickel ions and has an excellent endothelialization ability, a production method therefor, and a stent. The bio-hybrid material (101) used includes an alloy part (11) free of Ni, an organic acid (12) having two or more active esters, and a cytokine (13). The alloy part (11) free of Ni forms an ester bond with the organic acid (12), and the organic acid (12) and the cytokine (13) are immobilized via an amide bond.

Abstract: A nickel-free stainless steel stent using a stainless steel which does not substantially contain Ni in the stainless steel, has a metal allergy onset-preventing effect, and is excellent in terms of precision workability, strength, and ductility, is provided. The nickel-free stainless steel stent is characterized by using a stainless steel containing, as a chemical composition, from 15 to 30% by mass of Cr, from 0.97 to 2% by mass of Mo, and from 0.5 to 1% by mass of N, with the remainder being Fe, and optionally containing inevitable impurities.